Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 166

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 4
Chunk 166
---
id License Agreement as well as the shutdown of our U.S. commercial operations, we have refocused our operations on development activities in Israel in the fields of oncology and rare diseases, at a significantly reduced annual cash burn rate.

 We are continuing to advance the development of motixafortide for patients with pancreatic cancer and other solid tumors.

In addition, as part of our growth strategy, we are actively pursuing in-licensing opportunities to expand and diversify our product pipeline. We are specifically targeting innovative therapeutic candidates that complement our existing portfolio and align with our core expertise in oncology and rare disease. Our business development team is evaluating potential assets across various stages of development, from preclinical to late-stage clinical programs. We maintain a disciplined approach to asset acquisition, focusing on opportunities that offer significant market potential, address unmet medical needs, and can leverage our established development and commercialization capabilities. Through these strategic in-licensing efforts, we aim to enhance shareholder value while advancing our mission of bringing novel therapies to patients in need. See also “Item 4.B. Information on the Company — In-Licensing Agreements.”
 
<{self.tag} alt="{self.alt}" src="{self.src}">Our Product Pipeline
 
The table below summarizes key information about our products and our clinical programs:
 
 

Motixafortide
 
Motixafortide is a novel, short peptide that functions as a high-affinity antagonist of CXCR4, used in the treatment of stem cell mobilization and solid tumors. CXCR4 is expressed by normal hematopoietic cells and overexpressed in various human cancers where its expression correlates with disease severity. CXCR4 is a chemokine receptor that mediates the homing and retention of hematopoietic stem cells, or HSCs, in the bone marrow, and also mediates tumor progression, angiogenesis (growth of new blood vessels in the tumor), metastasis (spread of tumor to other organs) and survival. Before “motixafortide” was approved by the World Health Organization, or WHO, in 2019 as an International Nonproprietary Name, this therapeutic candidate was known as “BL-8040”. In October 2021, we received WHO approval of the United States Adopted Name, or USAN, “motixafortide”. The FDA-approved trade or brand name of motixafortide is APHEXDA.
 
Inhibition of CXCR4 by motixafortide leads to the mobilization of HSCs from the bone marrow to